source
- Epicrispr reports encouraging early data from EPI-321 in 12 patients with FSHDEpicrispr Biotechnologies released updated data on its epigenetic editing therapy EPI-321 aimed at treating facioscapulohumeral muscular dystrophy (FSHD). The company has now dosed twelve particip…
- Beam Therapeutics sues Chinese scientists and firms YolTech, Serapha Bio over alleged gene-editing technology theftBeam Therapeutics, a Cambridge-based company developing CRISPR base editing therapies, has filed a lawsuit. The suit names two Chinese scientists and the biotech firms YolTech and Serapha Bio, acc…